GLP-1 receptor agonists are a type of medication primarily prescribed for managing type 2 diabetes and have recently gained attention for their effectiveness in treating obesity. They function similarly to glucagon-like peptide-1 (GLP-1), a hormone that increases insulin production, delays stomach emptying, decreases glucagon release, and encourages feelings of fullness in response to meals. These medications aid in improving blood sugar homeostasis and may promote weight loss by increasing insulin sensitivity and decreasing hunger. Examples that have also demonstrated cardiovascular benefits include semaglutide and ligarglutide.
According to SPER Market Research, ‘Global GLP-1 Receptor Agonist Market Size- By Product, By Application, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2033’ states that the Global GLP-1 Receptor Agonist Market is estimated to reach USD 266.54 billion by 2033 with a CAGR of 21.9%.
Drivers: The rising prevalence of obesity and diabetes is expected to fuel this market's growth. Obesity and excess weight increase the risk of developing diabetes and heart disease. Obesity rates are rising worldwide, and it is widely acknowledged that this is one of the most significant public health issues of our day. Approximately 2.3 billion adults and children worldwide are overweight or obese, according to the World Heart Federation. Additionally, the Obesity Action Coalition (OAC) reports that over 90% of individuals with type 2 diabetes are overweight or obese to some degree. Therefore, the increasing number of persons with diabetes and obesity is driving the need for GLP-1 receptor agonist drugs for treatment on a global scale.
Download sample PDF copy of this report to understand structure of the complete report @ https://www.sperresearch.com/report-store/glp-1-receptor-agonist-market.aspx?sample=1
Restraints: GLP-1 receptor agonist accessibility and market growth may be hindered by a number of problems. Access to these treatments is frequently hampered by their high cost, particularly in areas with underdeveloped healthcare systems. Because they may discourage patients from adhering to their treatment plan, adverse consequences, like gastrointestinal problems, have also been raised. The competition from non-pharmacological approaches and newer drugs, as well as alternative diabetes and obesity treatments, makes things more challenging. Regulatory obstacles and the requirement for substantial clinical evidence to prove long-term safety and effectiveness could potentially make it more difficult for novel formulations to be approved.
COVID-19 Impact: The global market for GLP-1 receptor agonists was significantly impacted by the COVID-19 epidemic in a variety of ways. Initially, health care disruption resulted in fewer visits to patients and delayed identification of diabetes and obesity, which in turn led to fewer new prescriptions for these drugs. GLP-1 receptor agonist availability was also impacted by supply chain disruptions, leading to shortages in some areas. However, because those with diabetes were more vulnerable to COVID-19, the pandemic raised awareness of metabolic health and the need to manage these disorders.
In 2023, the North American GLP-1 receptor agonist market held a 76.19% market share. North America's market for GLP-1 receptor agonists is dominated by well-known brands such as Eli Lilly and Company; Novo Nordisk A/S; AstraZeneca, Sanofi.
Global GLP-1 Receptor Agonist Market Segmentation:
By Product: Based on the Product, Global GLP-1 Receptor Agonist Market is segmented as; Ozempic,k Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound, Other.
By Application: Based on the Application, Global GLP-1 Receptor Agonist Market is segmented as; Type 2 Diabetes Mellitus, Obesity.
By Route of Administration: Based on the Route of Administration, Global GLP-1 Receptor Agonist Market is segmented as; Parenteral, Oral.
By Distribution Channel: Based on the Distribution Channel, Global GLP-1 Receptor Agonist Market is segmented as; Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
By Region: This research also include data for North America, Europe, Asia-Pacific Middle East & Africa and South America.
For More Information in GLP-1 Receptor Agonist Market, refer to below link –
Others Industry Report –
Follow Us –
Contact Us:
Sara Lopes, Business Consultant – U.S.A.
SPER Market Research
+1-347-460-2899
Comments